© 2020 MJH Life Sciences and HCPLive. All rights reserved.
American Thoracic Society International Conference
GDC-0214 Well-Tolerated for Patients with Mild Asthma
August 08, 2020
Article
In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.
Tezepelumab Helps Reduce Severe Asthma Exacerbations
August 07, 2020
Article
In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.
Expanding the ETHOS Data
June 29, 2020
Article
Where do investigators go next with the 8000-plus COPD patient research?
Topline Sotatercept Results Positive Treating Pulmonary Arterial Hypertension
June 26, 2020
Article
Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.
Phase 3 Data Points to Treprostinil as a Treatment for Pulmonary Hypertension
June 25, 2020
Article
Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.
Individualizing COPD Care
June 25, 2020
Article
In an era of triple therapy combinations, what might a tailored approach look like?
Budesonide Plus LAMA/LABA Significantly Reduces Annual COPD Exacerbation
June 24, 2020
Article
New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.
Advancing Biologic Research in Asthma
May 27, 2020
Article
How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.
Denise Daley, PhD: Early Asthma Interventions for Infants
May 24, 2020
Article
Asthmatic infants often suffer from other comorbidities throughout their lives.
Continued Three-Year Mepolizumab Sustains Severe Asthma Benefits
May 23, 2020
Article
Blood eosinophil count, exacerbation rate, and time to exacerbation were all bettered among patients who sustained therapy versus those who discontinued.